Oxytocin to Enhance Integrated Treatment for AUD and PTSD
Oxytocin to Enhance Integrated Exposure-Based Treatment of Co-occurring Alcohol Use Disorder and PTSD
Medical University of South Carolina
180 participants
Mar 29, 2021
INTERVENTIONAL
Conditions
Summary
The primary objective of the proposed Stage II study is to examine the efficacy of oxytocin (OT) as compared to placebo in reducing (1) alcohol use disorder (AUD) symptoms, and (2) post-traumatic stress disorder (PTSD) symptoms among Veterans receiving COPE therapy (Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure). To evaluate purported neurobiological mechanisms of change, we will employ functional magnetic resonance imaging (fMRI) at pre- and post-treatment.
Eligibility
Inclusion Criteria4
- Male or female; U.S. military Veteran, any race or ethnicity; aged 18-70 years.
- Able to provide written informed consent.
- Meet DSM-5 diagnostic criteria for current moderate to severe alcohol use disorder.
- Meet DSM-5 diagnostic criteria for current PTSD as assessed by the CAPS-5.
Exclusion Criteria7
- Participants taking psychotropic medications will be required to be maintained on a stable dose for at least 4 weeks before study initiation.
- Meeting DSM-5 criteria for a history of or current psychotic or bipolar affective disorders, or with current suicidal or homicidal ideation and intent. Those participants will be referred clinically for services.
- Participants on psychotropic medications which have been initiated during the past 4 weeks.
- Acute alcohol withdrawal as indicated by CIWA-Ar scores \>8.
- Pregnancy or breastfeeding for women.
- For MRI scan component: history of seizures or severe head injury, implanted metal devices or other metal (e.g., shrapnel). These participants will be eligible to enroll in the clinical trial but will not be eligible to participate in the neuroimaging component of the study.
- Currently enrolled in behavioral treatment for AUD or PTSD.
Interventions
12 weekly sessions of COPE therapy for PTSD and AUD.
40 IU Intranasal Oxytocin self administered 30 minutes prior to each COPE session.
Placebo (intranasal saline spray) self administered 30 minutes prior to each COPE session.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04523922